Clinical Trial Update: APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202) [Phase 2]

View source ↗

Summary

The Phase 2 APRiCOT-B study evaluating Apricoxib with lapatinib and capecitabine for HER2-positive breast cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Apricoxib (apricoxib)
• Capecitabine (capecitabine)
• Lapatinib (Lapatinib)

Snippet

Sponsor: Tragara Pharmaceuticals, Inc. | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED